Vesnarinone for Heart Failure

K. Swedberg; H. Wedel; D. Neely; A. Schwartz; A. M. Feldman; M. R. Bristow; W. W. Parmley; M. Packer

doi:10.1056/NEJM199401063300114

Vesnarinone for Heart Failure

K. Swedberg, H. Wedel, D. Neely, A. Schwartz, A. M. Feldman, M. R. Bristow, W. W. Parmley, M. Packer

Clinical Sciences

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

To the Editor: In the report by Feldman et al. (July 15 issue)¹ we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done,…

Original language	English (US)
Pages (from-to)	64-66
Number of pages	3
Journal	New England Journal of Medicine
Volume	330
Issue number	1
DOIs	https://doi.org/10.1056/NEJM199401063300114
State	Published - Jan 6 1994

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199401063300114

Cite this

@article{adf3f655e6804d1d8e0c9d1f5c915ea9,

title = "Vesnarinone for Heart Failure",

abstract = "To the Editor: In the report by Feldman et al. (July 15 issue)1 we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done,…",

author = "K. Swedberg and H. Wedel and D. Neely and A. Schwartz and Feldman, {A. M.} and Bristow, {M. R.} and Parmley, {W. W.} and M. Packer",

year = "1994",

month = jan,

day = "6",

doi = "10.1056/NEJM199401063300114",

language = "English (US)",

volume = "330",

pages = "64--66",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "1",

}

TY - JOUR

T1 - Vesnarinone for Heart Failure

AU - Swedberg, K.

AU - Wedel, H.

AU - Neely, D.

AU - Schwartz, A.

AU - Feldman, A. M.

AU - Bristow, M. R.

AU - Parmley, W. W.

AU - Packer, M.

PY - 1994/1/6

Y1 - 1994/1/6

N2 - To the Editor: In the report by Feldman et al. (July 15 issue)1 we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done,…

AB - To the Editor: In the report by Feldman et al. (July 15 issue)1 we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done,…

UR - http://www.scopus.com/inward/record.url?scp=0028013584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028013584&partnerID=8YFLogxK

U2 - 10.1056/NEJM199401063300114

DO - 10.1056/NEJM199401063300114

M3 - Letter

C2 - 8259151

AN - SCOPUS:0028013584

SN - 0028-4793

VL - 330

SP - 64

EP - 66

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -

Vesnarinone for Heart Failure

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this